Morningstar Rating

Stock Research and Analysis

by Debbie S. Wang

Bulls Say

Hologic was first to market with an FDA-approved 3-D mammography platform in the United States, giving it a considerable head start against General Electric and Siemens.
Hologic controls the lion’s share of the U.S. liquid-based Pap market, and the Gen-Probe acquisition catapulted the firm into number one positions in testing for chlamydia, gonorrhea, and blood screening.
Government reimbursement for 3-D mammography appears lucrative for Hologic's customer base and should accelerate system placements in fiscal 2015. Read more 

Bears Say

Given the typically slow pace at which the medical community adopts new screening guidelines, it appears that a stabilization in ThinPrep volume declines is still a ways away.
While geographic expansion efforts are underway, Hologic has relatively little international exposure, leaving it with a heavy tax burden.
Despite Hologic’s full pipeline and best efforts, a high degree of clinical and regulatory risk surrounds its products. The regulatory path to approval can be an expensive, time-consuming, and fruitless process. Read more 

Management

We award Hologic standard marks for stewardship. The firm announced in December 2013 that Stephen MacMillan would replace Jack Cumming as CEO, who had returned to the role in July after having previously served in that capacity from 2001 to 2009. MacMillan   Read more 

Profile

Hologic manufactures proprietary products for the health-care needs of women. The company operates in four segments: diagnostics (48% of sales), breast health (36%), surgical   Read more 

Health Care a Leader in Moat Stocks 
Watch more 

Premium Membership

View all of our analyst reports with a free trial to Morningstar.com Premium.